Skip to main content
PMC home page
Journal of Virology logoLink to Journal of Virology
. 1996 Nov;70(11):7783–7791. doi: 10.1128/jvi.70.11.7783-7791.1996

Generation of atypical pulmonary inflammatory responses in BALB/c mice after immunization with the native attachment (G) glycoprotein of respiratory syncytial virus.

G E Hancock 1, D J Speelman 1, K Heers 1, E Bortell 1, J Smith 1, C Cosco 1
PMCID: PMC190848  PMID: 8892899

Abstract

The feasibility of using the highly purified native attachment (G) protein in a subunit vaccine against respiratory syncytial virus (RSV) was examined in a murine model with or without the fusion (F) protein of RSV and the adjuvant QS-21. The studies established that QS-21 was more potent than AIOH as an adjuvant for both F and G glycoproteins. Augmented antigen-dependent killer cell activity and complement-assisted serum neutralizing and anti-F and G protein immunoglobulin G2a antibody titers were observed. Immunization with G/QS-21 generated immune responses that were characterized by low levels of antigen-dependent killer cell activity, elevated levels of interleukin-5 (IL-5) and percentages of eosinophils in the bronchoalveolar lavage fluids after challenge, and splenic immunocytes that secreted IL-5 but not gamma interferon (IFN-gamma) after in vitro stimulation with purified whole virus antigens. The pulmonary eosinophilia was similar to that induced by a facsimile of a formalin-inactivated vaccine used in previous clinical trials and was prevented by prior in vivo treatment with anti-IL-5 but not with control immunoglobulin G or anti-IFN-gamma neutralizing monoclonal antibodies. Thus the data implied that vaccination with G/QS-21 generated helper T-cell immune responses that were type 2 in nature. Alternatively, the data suggested that the helper T-cell immune responses elicited by F/QS-21 were more type 1 in character. Neither eosinophilia nor elevated levels of IL-5 were observed in the lungs of mice after challenge. Noteworthy levels of antigen-dependent killer cell activity was observed, and splenic immunocytes secreted copious quantities of IFN-gamma. Immunization with a combination vaccine composed of highly purified native F and G proteins plus QS-21 (F+G/QS-21) resulted in augmented complement-assisted serum neutralizing antibody titers compared with vaccination with either F/QS-21 or G/QS-21 alone. However, following vaccination with F+G/QS-21, the bronchoalveolar lavage fluids contained significant increases in IL-5 and percentages of eosinophils after challenge, the spleen cells appeared to secrete less IFN-gamma after in vitro stimulation, and there was no evidence of increased numbers of antigen-dependent killer cell precursors. Taken together, the data imply that native G protein influences the nature of the immune responses elicited by F/QS-21. The results therefore suggest that G, not F, protein has more potential to bias the host for atypical pulmonary inflammatory responses.

Full Text

The Full Text of this article is available as a PDF (224.9 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alwan W. H., Kozlowska W. J., Openshaw P. J. Distinct types of lung disease caused by functional subsets of antiviral T cells. J Exp Med. 1994 Jan 1;179(1):81–89. doi: 10.1084/jem.179.1.81. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Alwan W. H., Record F. M., Openshaw P. J. Phenotypic and functional characterization of T cell lines specific for individual respiratory syncytial virus proteins. J Immunol. 1993 Jun 15;150(12):5211–5218. [PubMed] [Google Scholar]
  3. Belshe R. B., Van Voris L. P., Mufson M. A. Parenteral administration of live respiratory syncytial virus vaccine: results of a field trial. J Infect Dis. 1982 Mar;145(3):311–319. doi: 10.1093/infdis/145.3.311. [DOI] [PubMed] [Google Scholar]
  4. Brideau R. J., Wathen M. W. A chimeric glycoprotein of human respiratory syncytial virus termed FG induces T-cell mediated immunity in mice. Vaccine. 1991 Dec;9(12):863–864. doi: 10.1016/0264-410x(91)90003-o. [DOI] [PubMed] [Google Scholar]
  5. CHANOCK R. M., PARROTT R. H. ACUTE RESPIRATORY DISEASE IN INFANCY AND CHILDHOOD: PRESENT UNDERSTANDING AND PROSPECTS FOR PREVENTION. Pediatrics. 1965 Jul;36:21–39. [PubMed] [Google Scholar]
  6. Chanock R. M., Parrott R. H., Connors M., Collins P. L., Murphy B. R. Serious respiratory tract disease caused by respiratory syncytial virus: prospects for improved therapy and effective immunization. Pediatrics. 1992 Jul;90(1 Pt 2):137–143. [PubMed] [Google Scholar]
  7. Cherrie A. H., Anderson K., Wertz G. W., Openshaw P. J. Human cytotoxic T cells stimulated by antigen on dendritic cells recognize the N, SH, F, M, 22K, and 1b proteins of respiratory syncytial virus. J Virol. 1992 Apr;66(4):2102–2110. doi: 10.1128/jvi.66.4.2102-2110.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Coffman R. L., Seymour B. W., Hudak S., Jackson J., Rennick D. Antibody to interleukin-5 inhibits helminth-induced eosinophilia in mice. Science. 1989 Jul 21;245(4915):308–310. doi: 10.1126/science.2787531. [DOI] [PubMed] [Google Scholar]
  9. Colocho Zelaya E. A., Orvell C., Strannegård O. Eosinophil cationic protein in nasopharyngeal secretions and serum of infants infected with respiratory syncytial virus. Pediatr Allergy Immunol. 1994 May;5(2):100–106. doi: 10.1111/j.1399-3038.1994.tb00225.x. [DOI] [PubMed] [Google Scholar]
  10. Connors M., Collins P. L., Firestone C. Y., Sotnikov A. V., Waitze A., Davis A. R., Hung P. P., Chanock R. M., Murphy B. R. Cotton rats previously immunized with a chimeric RSV FG glycoprotein develop enhanced pulmonary pathology when infected with RSV, a phenomenon not encountered following immunization with vaccinia--RSV recombinants or RSV. Vaccine. 1992;10(7):475–484. doi: 10.1016/0264-410x(92)90397-3. [DOI] [PubMed] [Google Scholar]
  11. Connors M., Giese N. A., Kulkarni A. B., Firestone C. Y., Morse H. C., 3rd, Murphy B. R. Enhanced pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of interleukin-4 (IL-4) and IL-10. J Virol. 1994 Aug;68(8):5321–5325. doi: 10.1128/jvi.68.8.5321-5325.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Connors M., Kulkarni A. B., Firestone C. Y., Holmes K. L., Morse H. C., 3rd, Sotnikov A. V., Murphy B. R. Pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of CD4+ T cells. J Virol. 1992 Dec;66(12):7444–7451. doi: 10.1128/jvi.66.12.7444-7451.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Curry R. C., Kiener P. A., Spitalny G. L. A sensitive immunochemical assay for biologically active MuIFN-gamma. J Immunol Methods. 1987 Nov 23;104(1-2):137–142. doi: 10.1016/0022-1759(87)90497-2. [DOI] [PubMed] [Google Scholar]
  14. Dubucquoi S., Desreumaux P., Janin A., Klein O., Goldman M., Tavernier J., Capron A., Capron M. Interleukin 5 synthesis by eosinophils: association with granules and immunoglobulin-dependent secretion. J Exp Med. 1994 Feb 1;179(2):703–708. doi: 10.1084/jem.179.2.703. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Fernie B. F., Ford E. C., Gerin J. L. The development of Balb/c cells persistently infected with respiratory syncytial virus: presence of ribonucleoprotein on the cell surface. Proc Soc Exp Biol Med. 1981 May;167(1):83–86. doi: 10.3181/00379727-167-41129. [DOI] [PubMed] [Google Scholar]
  16. Garofalo R., Kimpen J. L., Welliver R. C., Ogra P. L. Eosinophil degranulation in the respiratory tract during naturally acquired respiratory syncytial virus infection. J Pediatr. 1992 Jan;120(1):28–32. doi: 10.1016/s0022-3476(05)80592-x. [DOI] [PubMed] [Google Scholar]
  17. Graham B. S., Henderson G. S., Tang Y. W., Lu X., Neuzil K. M., Colley D. G. Priming immunization determines T helper cytokine mRNA expression patterns in lungs of mice challenged with respiratory syncytial virus. J Immunol. 1993 Aug 15;151(4):2032–2040. [PubMed] [Google Scholar]
  18. Hall C. B., Walsh E. E., Long C. E., Schnabel K. C. Immunity to and frequency of reinfection with respiratory syncytial virus. J Infect Dis. 1991 Apr;163(4):693–698. doi: 10.1093/infdis/163.4.693. [DOI] [PubMed] [Google Scholar]
  19. Hancock G. E., Hahn D. J., Speelman D. J., Hildreth S. W., Pillai S., McQueen K. The pulmonary immune response of Balb/c mice vaccinated with the fusion protein of respiratory syncytial virus. Vaccine. 1994;12(3):267–274. doi: 10.1016/0264-410x(94)90204-6. [DOI] [PubMed] [Google Scholar]
  20. Hancock G. E., Speelman D. J., Frenchick P. J., Mineo-Kuhn M. M., Baggs R. B., Hahn D. J. Formulation of the purified fusion protein of respiratory syncytial virus with the saponin QS-21 induces protective immune responses in Balb/c mice that are similar to those generated by experimental infection. Vaccine. 1995 Mar;13(4):391–400. doi: 10.1016/0264-410x(95)98263-a. [DOI] [PubMed] [Google Scholar]
  21. Johnson P. R., Spriggs M. K., Olmsted R. A., Collins P. L. The G glycoprotein of human respiratory syncytial viruses of subgroups A and B: extensive sequence divergence between antigenically related proteins. Proc Natl Acad Sci U S A. 1987 Aug;84(16):5625–5629. doi: 10.1073/pnas.84.16.5625. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Kakuk T. J., Soike K., Brideau R. J., Zaya R. M., Cole S. L., Zhang J. Y., Roberts E. D., Wells P. A., Wathen M. W. A human respiratory syncytial virus (RSV) primate model of enhanced pulmonary pathology induced with a formalin-inactivated RSV vaccine but not a recombinant FG subunit vaccine. J Infect Dis. 1993 Mar;167(3):553–561. doi: 10.1093/infdis/167.3.553. [DOI] [PubMed] [Google Scholar]
  23. Kapikian A. Z., Mitchell R. H., Chanock R. M., Shvedoff R. A., Stewart C. E. An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am J Epidemiol. 1969 Apr;89(4):405–421. doi: 10.1093/oxfordjournals.aje.a120954. [DOI] [PubMed] [Google Scholar]
  24. Kensil C. R., Patel U., Lennick M., Marciani D. Separation and characterization of saponins with adjuvant activity from Quillaja saponaria Molina cortex. J Immunol. 1991 Jan 15;146(2):431–437. [PubMed] [Google Scholar]
  25. Kim H. W., Arrobio J. O., Brandt C. D., Wright P., Hodes D., Chanock R. M., Parrott R. H. Safety and antigenicity of temperature sensitive (TS) mutant respiratory syncytial virus (RSV) in infants and children. Pediatrics. 1973 Jul;52(1):56–63. [PubMed] [Google Scholar]
  26. Kim H. W., Arrobio J. O., Pyles G., Brandt C. D., Camargo E., Chanock R. M., Parrott R. H. Clinical and immunological response of infants and children to administration of low-temperature adapted respiratory syncytial virus. Pediatrics. 1971 Nov;48(5):745–755. [PubMed] [Google Scholar]
  27. Kim H. W., Canchola J. G., Brandt C. D., Pyles G., Chanock R. M., Jensen K., Parrott R. H. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol. 1969 Apr;89(4):422–434. doi: 10.1093/oxfordjournals.aje.a120955. [DOI] [PubMed] [Google Scholar]
  28. Kim H. W., Leikin S. L., Arrobio J., Brandt C. D., Chanock R. M., Parrott R. H. Cell-mediated immunity to respiratory syncytial virus induced by inactivated vaccine or by infection. Pediatr Res. 1976 Jan;10(1):75–78. doi: 10.1203/00006450-197601000-00015. [DOI] [PubMed] [Google Scholar]
  29. Kimpen J. L., Garofalo R., Welliver R. C., Ogra P. L. Activation of human eosinophils in vitro by respiratory syncytial virus. Pediatr Res. 1992 Aug;32(2):160–164. doi: 10.1203/00006450-199208000-00007. [DOI] [PubMed] [Google Scholar]
  30. Lammas D. A., Mitchell L. A., Wakelin D. Genetic control of eosinophilia. Analysis of production and response to eosinophil-differentiating factor in strains of mice infected with Trichinella spiralis. Clin Exp Immunol. 1989 Jul;77(1):137–143. [PMC free article] [PubMed] [Google Scholar]
  31. Ma J., Bulger P. A., Davis D. R., Perilli-Palmer B., Bedore D. A., Kensil C. R., Young E. M., Hung C. H., Seals J. R., Pavia C. S. Impact of the saponin adjuvant QS-21 and aluminium hydroxide on the immunogenicity of recombinant OspA and OspB of Borrelia burgdorferi. Vaccine. 1994 Aug;12(10):925–932. doi: 10.1016/0264-410x(94)90036-1. [DOI] [PubMed] [Google Scholar]
  32. Mosmann T. R., Schumacher J. H., Street N. F., Budd R., O'Garra A., Fong T. A., Bond M. W., Moore K. W., Sher A., Fiorentino D. F. Diversity of cytokine synthesis and function of mouse CD4+ T cells. Immunol Rev. 1991 Oct;123:209–229. doi: 10.1111/j.1600-065x.1991.tb00612.x. [DOI] [PubMed] [Google Scholar]
  33. Muelenaer P. M., Henderson F. W., Hemming V. G., Walsh E. E., Anderson L. J., Prince G. A., Murphy B. R. Group-specific serum antibody responses in children with primary and recurrent respiratory syncytial virus infections. J Infect Dis. 1991 Jul;164(1):15–21. doi: 10.1093/infdis/164.1.15. [DOI] [PubMed] [Google Scholar]
  34. Murphy B. R., Alling D. W., Snyder M. H., Walsh E. E., Prince G. A., Chanock R. M., Hemming V. G., Rodriguez W. J., Kim H. W., Graham B. S. Effect of age and preexisting antibody on serum antibody response of infants and children to the F and G glycoproteins during respiratory syncytial virus infection. J Clin Microbiol. 1986 Nov;24(5):894–898. doi: 10.1128/jcm.24.5.894-898.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Murphy B. R., Hall S. L., Kulkarni A. B., Crowe J. E., Jr, Collins P. L., Connors M., Karron R. A., Chanock R. M. An update on approaches to the development of respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV3) vaccines. Virus Res. 1994 Apr;32(1):13–36. doi: 10.1016/0168-1702(94)90059-0. [DOI] [PubMed] [Google Scholar]
  36. Murphy B. R., Prince G. A., Walsh E. E., Kim H. W., Parrott R. H., Hemming V. G., Rodriguez W. J., Chanock R. M. Dissociation between serum neutralizing and glycoprotein antibody responses of infants and children who received inactivated respiratory syncytial virus vaccine. J Clin Microbiol. 1986 Aug;24(2):197–202. doi: 10.1128/jcm.24.2.197-202.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Newman M. J., Wu J. Y., Gardner B. H., Munroe K. J., Leombruno D., Recchia J., Kensil C. R., Coughlin R. T. Saponin adjuvant induction of ovalbumin-specific CD8+ cytotoxic T lymphocyte responses. J Immunol. 1992 Apr 15;148(8):2357–2362. [PubMed] [Google Scholar]
  38. Noble A., Macary P. A., Kemeny D. M. IFN-gamma and IL-4 regulate the growth and differentiation of CD8+ T cells into subpopulations with distinct cytokine profiles. J Immunol. 1995 Sep 15;155(6):2928–2937. [PubMed] [Google Scholar]
  39. Piedra P. A., Wyde P. R., Castleman W. L., Ambrose M. W., Jewell A. M., Speelman D. J., Hildreth S. W. Enhanced pulmonary pathology associated with the use of formalin-inactivated respiratory syncytial virus vaccine in cotton rats is not a unique viral phenomenon. Vaccine. 1993 Nov;11(14):1415–1423. doi: 10.1016/0264-410x(93)90170-3. [DOI] [PubMed] [Google Scholar]
  40. Sad S., Marcotte R., Mosmann T. R. Cytokine-induced differentiation of precursor mouse CD8+ T cells into cytotoxic CD8+ T cells secreting Th1 or Th2 cytokines. Immunity. 1995 Mar;2(3):271–279. doi: 10.1016/1074-7613(95)90051-9. [DOI] [PubMed] [Google Scholar]
  41. Salgame P., Abrams J. S., Clayberger C., Goldstein H., Convit J., Modlin R. L., Bloom B. R. Differing lymphokine profiles of functional subsets of human CD4 and CD8 T cell clones. Science. 1991 Oct 11;254(5029):279–282. doi: 10.1126/science.254.5029.279. [DOI] [PubMed] [Google Scholar]
  42. Satake M., Coligan J. E., Elango N., Norrby E., Venkatesan S. Respiratory syncytial virus envelope glycoprotein (G) has a novel structure. Nucleic Acids Res. 1985 Nov 11;13(21):7795–7812. doi: 10.1093/nar/13.21.7795. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Spitalny G. L., Havell E. A. Monoclonal antibody to murine gamma interferon inhibits lymphokine-induced antiviral and macrophage tumoricidal activities. J Exp Med. 1984 May 1;159(5):1560–1565. doi: 10.1084/jem.159.5.1560. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Stanley C. J., Johannsson A., Self C. H. Enzyme amplification can enhance both the speed and the sensitivity of immunoassays. J Immunol Methods. 1985 Oct 24;83(1):89–95. doi: 10.1016/0022-1759(85)90061-4. [DOI] [PubMed] [Google Scholar]
  45. Storch G. A., Anderson L. J., Park C. S., Tsou C., Dohner D. E. Antigenic and genomic diversity within group A respiratory syncytial virus. J Infect Dis. 1991 Apr;163(4):858–861. doi: 10.1093/infdis/163.4.858. [DOI] [PubMed] [Google Scholar]
  46. Stott E. J., Taylor G. Respiratory syncytial virus. Brief review. Arch Virol. 1985;84(1-2):1–52. doi: 10.1007/BF01310552. [DOI] [PubMed] [Google Scholar]
  47. Taylor G., Stott E. J., Bew M., Fernie B. F., Cote P. J., Collins A. P., Hughes M., Jebbett J. Monoclonal antibodies protect against respiratory syncytial virus infection in mice. Immunology. 1984 May;52(1):137–142. [PMC free article] [PubMed] [Google Scholar]
  48. Toms G. L. Vaccination against respiratory syncytial virus: problems and progress. FEMS Microbiol Immunol. 1991 Oct;3(5):243–256. doi: 10.1111/j.1574-6968.1991.tb04221.x. [DOI] [PubMed] [Google Scholar]
  49. Trinchieri G. Interleukin-12: a cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-helper cells type 1 and cytotoxic lymphocytes. Blood. 1994 Dec 15;84(12):4008–4027. [PubMed] [Google Scholar]
  50. Tristram D. A., Welliver R. C., Mohar C. K., Hogerman D. A., Hildreth S. W., Paradiso P. Immunogenicity and safety of respiratory syncytial virus subunit vaccine in seropositive children 18-36 months old. J Infect Dis. 1993 Jan;167(1):191–195. doi: 10.1093/infdis/167.1.191. [DOI] [PubMed] [Google Scholar]
  51. Trudel M., Nadon F., Séguin C., Binz H. Protection of BALB/c mice from respiratory syncytial virus infection by immunization with a synthetic peptide derived from the G glycoprotein. Virology. 1991 Dec;185(2):749–757. doi: 10.1016/0042-6822(91)90546-n. [DOI] [PubMed] [Google Scholar]
  52. Walsh E. E., Schlesinger J. J., Brandriss M. W. Protection from respiratory syncytial virus infection in cotton rats by passive transfer of monoclonal antibodies. Infect Immun. 1984 Feb;43(2):756–758. doi: 10.1128/iai.43.2.756-758.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  53. Walsh E. E., Schlesinger J. J., Brandriss M. W. Purification and characterization of GP90, one of the envelope glycoproteins of respiratory syncytial virus. J Gen Virol. 1984 Apr;65(Pt 4):761–767. doi: 10.1099/0022-1317-65-4-761. [DOI] [PubMed] [Google Scholar]
  54. Warren H. S., Kinnear B. F., Phillips J. H., Lanier L. L. Production of IL-5 by human NK cells and regulation of IL-5 secretion by IL-4, IL-10, and IL-12. J Immunol. 1995 May 15;154(10):5144–5152. [PubMed] [Google Scholar]

Articles from Journal of Virology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES